

Message

From: Sauerhage, Maggie [Sauerhage.Maggie@epa.gov]
Sent: 7/2/2021 1:35:13 PM
To: Ross, Mary [Ross.Mary@epa.gov]; Deener, Kathleen [Deener.Kathleen@epa.gov]; Grifo, Francesca [Grifo.Francesca@epa.gov]
Subject: RE: Review today: Intercept inquiry on SI

Good morning – here's the Intercept article: <https://theintercept.com/2021/07/02/epa-chemical-safety-corruption-whistleblowers/>

Thanks,
Maggie

Maggie Sauerhage (she/her)
Office of Science Advisor Policy and Engagement
Office of Research and Development
U.S. Environmental Protection Agency
Office: (202) 564-0443
Cell: (202) 704-6352

From: Ross, Mary <Ross.Mary@epa.gov>
Sent: Thursday, July 01, 2021 1:35 PM
To: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>; Deener, Kathleen <Deener.Kathleen@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>
Subject: RE: Review today: Intercept inquiry on SI

Looks great, thanks!

From: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>
Sent: Thursday, July 1, 2021 1:34 PM
To: Deener, Kathleen <Deener.Kathleen@epa.gov>; Ross, Mary <Ross.Mary@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>
Subject: RE: Review today: Intercept inquiry on SI

Okay, thank you. I will also share your comment about Ex. 5 Deliberative Process (DP) when I send this forward. Mary, please let me know if you have any additional comments or edits. Thanks!

Draft EPA statement:

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Maggie Sauerhage (she/her)
Office of Science Advisor Policy and Engagement
Office of Research and Development
U.S. Environmental Protection Agency
Office: (202) 564-0443
Cell: (202) 704-6352

From: Deener, Kathleen <Deener.Kathleen@epa.gov>
Sent: Thursday, July 01, 2021 1:32 PM
To: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>; Ross, Mary <Ross.Mary@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>
Subject: RE: Review today: Intercept inquiry on SI

Yes. I like that order better.

Kacee Deener, MPH (she/her/hers)
Deputy Director, Office of Science Advisor Policy & Engagement
Office of Research and Development
U.S. Environmental Protection Agency
(mobile) 202.510.1490
deener.kathleen@epa.gov

From: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>
Sent: Thursday, July 1, 2021 1:29 PM
To: Deener, Kathleen <Deener.Kathleen@epa.gov>; Ross, Mary <Ross.Mary@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>
Subject: RE: Review today: Intercept inquiry on SI

Thanks Kacee – that looks good! For the last sentence, I assume they are referencing the complaints Sharon outlines in her message but maybe having the SI sentence there makes it more confusing. I moved it up, does that work better?

Maggie Sauerhage (she/her)
Office of Science Advisor Policy and Engagement
Office of Research and Development
U.S. Environmental Protection Agency
Office: (202) 564-0443
Cell: (202) 704-6352

From: Deener, Kathleen <Deener.Kathleen@epa.gov>
Sent: Thursday, July 01, 2021 1:26 PM

To: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>; Ross, Mary <Ross.Mary@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>

Subject: RE: Review today: Intercept inquiry on SI

Hi Maggie – a few thoughts and suggestions (my additions are in blue). Note, I don't know what Ex. 5 Deliberative Process (DP) means in this context, so I suggested different words there. I don't know about the last sentence – I Ex. 5 Deliberative Process (DP) assume if OPA added it, then they know this is happening or will happen. It might also be good to clarify what “these complaints” refer to in the last sentence. Is it tied to the four individuals described in the Intercept request? Or is it tied to the broader group of allegations referred to the in preceding sentence?

Draft EPA statement:

Ex. 5 Deliberative Process (DP)

Kacee Deener, MPH (she/her/hers)
Deputy Director, Office of Science Advisor Policy & Engagement
Office of Research and Development
U.S. Environmental Protection Agency
(mobile) 202.510.1490
deener.kathleen@epa.gov

From: Sauerhage, Maggie <Sauerhage.Maggie@epa.gov>

Sent: Thursday, July 1, 2021 12:40 PM

To: Ross, Mary <Ross.Mary@epa.gov>; Deener, Kathleen <Deener.Kathleen@epa.gov>; Grifo, Francesca <Grifo.Francesca@epa.gov>

Subject: Review today: Intercept inquiry on SI

Hi there – OPA shared the below draft statement for our review in response to an inquiry from Sharon Lerner at the Intercept. She received information that OCSPP employees had filed complaints with OIG and the SI team that OCSPP management (both in the current and previous administration) pressured them to change assessments of chemicals to make them appear safer. The inquiry + draft OPA response is below, which is also under review by OCSPP and OGC. This is due by 4pm today. Can you please take a look? I provided some draft language we could recommend adding since the information Sharon sent says that some of these folks filed complaints with the SI office (I highlighted that section below). After your review, I will share with Sam to share with Jennifer as well. Not sure if Francesca is checking email but copying her just in case. Thanks!

Ex. 5 Deliberative Process (DP)

Inquiry from Sharon:

I have written a quick piece about a complaint I received from whistleblowers in the OCSPP and PEER. I am pasting in what they have told me below. Please respond to the following - all of which was provided by the four scientists, [Ex. 6 Personal Privacy (PP)] by the end of the day today.

Thank you,
Sharon

Four scientists who work at EPA said that managers and career staff in the agency's Office of Chemical Safety and Pollution Prevention tampered with the assessments of dozens of chemicals to make them appear safer. The whistleblowers provided The Intercept with detailed evidence of pressure within the agency to minimize or remove evidence of potential adverse effects of the chemicals, including neurological effects, birth defects, and cancer.

On several occasions, information about hazards was deleted from agency assessments without informing or seeking the consent of the scientists who authored them. Some of these cases led the EPA to withhold critical information from the public about potentially dangerous chemical exposures. In other cases, the removal of the hazard information or the altering of the scientists' conclusions in reports paved the way for the use of chemicals, which otherwise would not have been allowed onto the market.

The four EPA staff members said that they told colleagues and supervisors within the agency about the interference with their work. Each of the scientists also filed complaints with either the EPA's Inspector General or the Office of Science Integrity.

In the case of one substance that [Ex. 6 Personal Privacy (PP)] was reviewing in February of this year, the animal studies suggested serious potential for harm. Rats exposed to a single dose of the chemical had become lethargic, lost weight, and had trouble moving. Some became comatose, and others died.

"Usually with this type of acute study, there are no effects," said [Ex. 6 Personal Privacy (PP)]. "So this was a red flag to me that we needed further information." But when [Ex. 6 Personal Privacy (PP)] said in a meeting that she needed more data to complete her hazard assessment report, one of her supervisors responded with a series of questions. "She kept asking me, 'Look at the data, look at the data, look at it again, tell me what you see,'" [Ex. 6 Personal Privacy (PP)] said of her supervisor. "I knew she wanted me to make the hazards go away and she even said that — 'why don't you take a look at the actual study data again, and maybe the hazards will go away?'"

A chemist named [Ex. 6 Personal Privacy (PP)] faced similar pushback when he was assessing a mixture of compounds in January of 2020. One component of the product, which was to be used in cleaning solutions, is a chemical that caused birth defects and miscarriage in experiments on rats. [Ex. 6 Personal Privacy (PP)] and another risk assessor noted the developmental effects in

the chemical's hazard assessment, which must by law then be added to the chemical's Safety Data Sheet. But the company that had submitted the product for approval balked at the requirement. And the day after the assessment [Ex. 6 Personal Privacy (PP)] wrote was finalized, a representative of the company who had recently worked in the same division of EPA met with several of [Ex. 6 Personal Privacy (PP)] colleagues and his supervisor whom she had known from her time at the agency. [Ex. 6 Personal Privacy (PP)] wasn't invited to attend the meeting. The following day, another assessment of the chemical was uploaded into the EPA's computer system without [Ex. 6 Personal Privacy (PP)] consent or knowledge. The new version omitted the information about the birth defects and miscarriages.

When he learned of the new assessment, [Ex. 6 Personal Privacy (PP)] asked that the original one be restored. The meeting that followed was hostile, with a senior science advisor in the office calling [Ex. 6 Personal Privacy (PP)] "passive aggressive" for being so concerned about the assessment. While some information about the chemical was restored in the assessment after [Ex. 6 Personal Privacy (PP)] complained about its removal, the warning about its potential to cause developmental toxicity, which would alert pregnant women to these harms, never made it into the safety data sheet.

[Ex. 6 Personal Privacy (PP)] had his work revised without his knowledge on other occasions, too. In one case in 2019, he was asked to assess a chemical even though the manufacturer had not submitted studies. [Ex. 6 Personal Privacy (PP)] followed the EPA's written guidance for such situations and used toxicity numbers for the class to which the chemical belongs. When he plugged in the proper values, [Ex. 6 Personal Privacy (PP)] calculated that the likely exposures to the chemical would exceed the agency's safety limit by more than 15,000 times. Three months after he submitted the document with this conclusion, he noticed that a new assessment of the chemical had been uploaded to the EPA's computer system. In this new assessment, which deviated from guidelines, the assessor found that the chemical posed only a slight risk and that workers who used the material could mitigate the danger by wearing protective gear.

The second assessment, which found the chemical not likely to pose harm, was finalized in August 2020.

All four scientists said the pressure to downplay the risk of chemicals increased during their time in the division. [Ex. 6 Personal Privacy (PP)] protested changes in multiple risk assessments between March and June 2020. Her supervisors asked her to represent the developmental effects of one chemical, which included the reduction of fetal weight in animal studies, as effects on the mothers. Such a mischaracterization would mean that the risk the chemical poses to a developing human fetus would not be reflected by its Safety Data Sheet, a document the Occupational Safety and Health Administration uses to communicate risk to workers. [Ex. 6 Personal Privacy (PP)] refused to make the change.

One month later, she was reassigned to another office.

Even after her transfer, documents she had written while in the Office of Chemical Safety and Pollution Prevention continued to be altered, including an assessment of a PFAS compound. Because there was limited information available about the chemical, she had looked to studies of similarly structured compounds, as is EPA policy. In this case, one of the closest analogues was PFOA, an industrial chemical that poses both cancer and developmental risks, as [Ex. 6 Personal Privacy (PP)] noted in her assessment. But one of her former supervisors had instructed another scientist to remove her reference to PFOA from the assessment and replace it with another, less toxic chemical to gauge its safety. The change resulted in a 33-fold underestimation of the compound's risk, according to [Ex. 6 Personal Privacy (PP)].

[Ex. 6 Personal Privacy (PP)] another of the four whistleblowers, who has worked at the EPA for over 11 years as a toxicologist, was also moved out of the office after repeatedly resisting pressure to change his assessments to favor industry. [Ex. 6 Personal Privacy (PP)] said that while it had seemed obvious that the pressure stemmed from chemical companies, the science advisor in the office made the point irrefutably clear during an argument over one particular chemical assessment.

"At one point, he was shouting at me to change it," [Ex. 6 Personal Privacy (PP)] said of the science advisor, who was urging him to eliminate hazards noted in the assessment. "He basically was siding with the company, shouting at me that 'the company went ape-shit when they saw this document.'" [Ex. 6 Personal Privacy (PP)] replied, "Well that's the assessment."

Ex. 5 Personal Privacy (PP) didn't make the changes. "I actually added extra hazards to it," he said. "It was also a carcinogen." Several months after that encounter, the antagonism stopped when Irwin was transferred out of the office. The scientist saw the move as a last resort for his managers. "I have three board certifications in toxicology, so it was hard for them to say Ex. 5 Personal Privacy (PP) you're stupid,' and so instead they just kicked me out of the program."

Ex. 5 Personal Privacy (PP) was also transferred in September 2020. Meanwhile Ex. 5 Personal Privacy (PP) continues to work in the office, where she said disputes over chemical assessments and retaliation against her have continued unabated.

Kyla Bennet from PEER said: "The problems in OCSPP are not due solely to the Trump Administration and its appointees. The issues faced by our clients occurred before Trump took office, during the Trump years, and continue now."

While such complaints are usually kept confidential, by Tuesday many managers in OCSPP had somehow obtained a copy of the whistleblowers' allegations. Bennett said: "The fact that EPA released our clients' names is inappropriate and troubling. They've been put in an incredibly uncomfortable situation. This gives the managers the chance to circle the wagons trying to go after them."

Maggie Sauerhage (she/her)
Office of Science Advisor Policy and Engagement
Office of Research and Development
U.S. Environmental Protection Agency
Office: (202) 564-0443
Cell: (202) 704-6352